Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 732

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 9A
Chunk 732
---
 Average   Remaining          Exercise   Contractual      Outstanding   Price Per   Life      Shares   Share   (in Years)   Balance, December 31, 2023 (Predecessor)   504   $418.92    6.86   Options cancelled (Predecessor)   (504)  $418.92        Balance, February 14, 2024 (Predecessor)   -   $-    -                     Balance, February 14, 2024 (Predecessor)   -   $-    -   Options granted (Successor)   98,180   $90.91    -   Options cancelled (Successor)   (33,232)  $146.12    -   Balance, December 31, 2024 (Successor)   64,948   $10.00    9.64   Options exercisable as of December 31, 2024   49,480   $10.00    9.68  

The intrinsic value of Predecessor
options exercised during the year ended December 31, 2023 was $9,458. No options were exercised in the Successor period from February
14, 2024 to December 31, 2024.

On March 25, 2024, the stockholders approved the CERo Therapeutics
Holdings, Inc. 2024 Equity Incentive Plan (the “2024 Plan”) and 2024 Employee Stock Purchase Plan (“2024 ESPP”),
with an initial reserve of 51,726 and 50,993 shares of common stock, respectively. The 2024 Plan and 2024 ESPP became effective on February
14, 2024 in connection with the closing of the Business Combination. At a special meeting of stockholders on April 30, 2024, the stockholders
approved an increase in the number of shares available for issuance under the 2024 Plan and the number of shares that may be issued pursuant
to incentive stock options, by an additional 20,000 shares each. At a special meeting of stockholders on November 11, 2024, the stockholders
approved an increase in the number of shares available